Flecainide for the Treatment of Chronic Neuropathic Pain: A Phase II Trial
OBJECTIVES:
- Investigate the effectiveness of flecainide in the management of neuropathic pain.
OUTLINE: Patients are given a brief pain inventory (BPI) form to assess their pain upon
enrollment in the study. Following a 7 day stabilization period, flecainide is administered.
One capsule of flecainide is given twice a day on days 8-10, two capsules are given twice a
day on days 11-14 and three capsules are given twice a day on days 15-21. BPI forms are
completed on days 8, 15 and 22 to assess neuropathic pain.
PROJECTED ACCRUAL: A total of 7-20 patients will be accrued for this study.
Interventional
Primary Purpose: Supportive Care
Charles F. Von Gunten, MD, PhD
Study Chair
Robert H. Lurie Cancer Center
United States: Food and Drug Administration
CDR0000065544
NCT00002996
February 1998
Name | Location |
---|---|
Mayo Clinic Cancer Center | Rochester, Minnesota 55905 |
CCOP - Iowa Oncology Research Association | Des Moines, Iowa 50309-1016 |
CCOP - Kalamazoo | Kalamazoo, Michigan 49007-3731 |
CCOP - Cedar Rapids Oncology Project | Cedar Rapids, Iowa 52403-1206 |
CCOP - Sioux Community Cancer Consortium | Sioux Falls, South Dakota 57105-1080 |
University of Wisconsin Comprehensive Cancer Center | Madison, Wisconsin 53792 |